Posts Archive

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma This early phase I trial studies the side effects of...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Recruitment Status: Enrolling by invitation...

CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...

DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...

NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01) Sponsor Trillium Therapeutics...

NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Testing the Addition...

NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma A Safety, PK and Efficacy Study of...

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) A Phase...

(PRIME) NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) NCT03288493: Phase...

The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...

Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Phase II Multicenter Trial of Single Autologous Hematopoietic...

AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...

NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...

The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...

NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by...